CA
MDGL icon

CoreCap Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

CoreCap Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
280
+3
+1% +$1.54K ﹤0.01% 961
2026
Q1 		$145K Buy
277
+195
+238% +$93.2K ﹤0.01% 899
2025
Q4 		$47.8K Buy
82
+14
+21% +$7.15K ﹤0.01% 1361
2025
Q3 		$31.2K Hold
68
– – ﹤0.01% 1502
2025
Q2 		$20.6K Hold
68
– – ﹤0.01% 1606
2025
Q1 		$22.5K Hold
68
– – ﹤0.01% 1485
2024
Q4 		$21K Hold
68
– – ﹤0.01% 1519
2024
Q3 		$14.4K Buy
+68
New +$17.4K ﹤0.01% 1675
2024
Q2 		– Sell
-68
Closed -$18.2K – 2209
2024
Q1 		$18.2K Buy
+68
New +$16K ﹤0.01% 1524
2022
Q4 		$19.7K Buy
+68
New +$6.65K ﹤0.01% 1312
2022
Q3 		– Sell
-68
Closed -$5K – 1443
2022
Q2 		$5K Buy
+68
New +$5K ﹤0.01% 1678
2022
Q1 		– Sell
-68
Closed -$6K – 1441
2021
Q4 		$6K Buy
+68
New +$5.59K ﹤0.01% 1705

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CoreCap Advisors's MDGL Position: Q2 2026 in Review

CoreCap Advisors increased its Madrigal Pharmaceuticals (MDGL) stake by 1.1% in Q2 2026, buying an estimated $1.54K and bringing the position to 280 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #961.

CoreCap Advisors first reported a position in MDGL in Q4 2021 and has held it in 12 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • CoreCap Advisors held 280 shares of Madrigal Pharmaceuticals worth $150K as of Q2 2026.
  • CoreCap Advisors bought 3 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $1.54K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #961 holding.
  • CoreCap Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.